Hepatocellular carcinoma;Hepatozelluläres karzinom

Therapeutische Umschau

Volumn 68, Issue 4, 2011, Pages 213-217

  Semela, David ^a   Heim, Markus ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ABLATION THERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOEMBOLIZATION; CHRONIC LIVER DISEASE; EARLY DIAGNOSIS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER SURGERY; LIVER TRANSPLANTATION;

BIOPSY; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; COMBINED MODALITY THERAPY; HEPATITIS, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MASS SCREENING; NEOPLASM STAGING; PREVALENCE; PROGNOSIS; ULTRASONOGRAPHY;

EID: 79953299370     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930/a000153     Document Type: Article

References (22)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. The New England journal of medicine. 1999 Mar 11; 340: 745-50.
2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004 Nov; 127: S27-34.
3. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenter-ology. 2004 Nov; 127: S5-S16.
4. Mullhaupt B, Junker C, Wuest E, Renner EL. Mortality from primary liver cancer in Switzerland from 1975 to 1994. Swiss Med Wkly. 2008 May 31; 138: 313-6.
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 Mar-Apr; 55: 74-108.
6. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. Journal of cancer research and clinical oncology. 2004 Jul; 130: 417-22.
7. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001 Feb; 48: 251-9.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology (Baltimore, Md. 2005 Nov; 42: 1208-36.
9. Bialecki ES, Ezenekwe AM, Brunt EM, Collins BT, Ponder TB, Biene-man BK, et al. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006 Mar; 4: 361-8.
10. Libbrecht L, Bielen D, Verslype C, Vanbeckevoort D, Pirenne J, Nevens F, et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplan-tation imaging examinations. Liver Transpl. 2002 Sep; 8: 749-61.
11. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocel-lular carcinomas in patients with cirrhosis. The New England journal of medicine. 1996 Mar 14; 334: 693-9.
12. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997 Feb; 112: 463-72.
13. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology (Baltimore, Md. 1999 Dec; 30: 1434-40.
14. Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, et al. Predictive factors for postoperative recurrence of hepatocellu-lar carcinoma. Gastroenterology. 1994 Jun; 106: 1618-24.
15. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocel-lular carcinoma: long-term results of treatment and prognostic factors. Annals of surgery. 1999 Feb; 229: 216-22.
16. Majno P, Mentha G, Toso C. Transplantation for hepatocellular carcinoma: Management of patients on the waiting list. Liver Transpl. Oct; 16: S2-S11.
17. Arii S, Yamaoka Y, Futagawa S, In-oue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepato-cellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology (Baltimore, Md. 2000 Dec; 32: 1224-9.
18. Sala M, Llovet JM, Vilana R, Bia n c hi L, Sole M, Ayuso C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepa-tology (Baltimore, Md. 2004 Dec; 40: 1352-60.
19. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, et al. He-patocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology. 1995 Oct; 197: 101-8.
20. Llovet JM, Bruix J. Systematic review of randomized trials for unre-sectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (Baltimore, Md. 2003 Feb; 37: 429-42.
21. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocel-lular carcinoma. The New England journal of medicine. 2008 Jul 24; 359: 378-90.
22. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Seminars in liver disease. Feb; 30: 61-74.